Generalized vitiligo
MONDO:1010125Any form of vitiligo characterized by loss of pigment (depigmentation) in patches of skin all over the body.
Also known as: generalised vitiligo, mixed vitiligo
52 clinical trials for this condition and its sub-types, 16 tagged with Generalized vitiligo itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a pill keep vitiligo at bay? new study aims to find out
Disease control OngoingThis study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to colo…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis phase 3 trial tests an oral drug called povorcitinib in about 467 adults with nonsegmental vitiligo, a condition causing white patches on the skin. Participants take the drug or a placebo daily for 52 weeks to see if it safely improves skin color on the face and body. The go…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Promising pill may halt vitiligo and bring back pigment
Disease control OngoingThis phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also rece…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill shows promise for vitiligo in major trial
Disease control OngoingThis study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to m…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC